Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HBS-104 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Crossover: HBS-104 Low Dose | EXPERIMENTAL | Participants will receive a single oral low dose of HBS-104. |
| Crossover: HBS-104 Medium Dose | EXPERIMENTAL | Participants will receive a single oral medium dose of HBS-104. |
| Crossover: HBS-104 High Dose | EXPERIMENTAL | Participants will receive a single oral high dose of HBS-104. |
| Crossover: Placebo | ACTIVE_COMPARATOR | Participants will receive a single oral dose of placebo. |
| Name | Type | Description |
|---|---|---|
| HBS-104 | DRUG | Immediate-release tablets for oral use |
| Placebo | DRUG | Matching placebo tablet |
Inclusion Criteria: * Provide written informed consent before any study-related procedures are performed. * Be healthy as determined by assessments at the Screening Visit. Exclusion Criteria: * Female with a positive pregnancy test at Screening Visit or upon check-in for Period 1. * Is currently ...
HBS-104 is an investigational small molecule being developed by Harmony Biosciences Holdings, Inc. for sleep deprivation. It is in Phase 1 clinical development and has not been approved by the FDA. The program is in the psychiatry therapeutic area and is being studied in healthy adult volunteers.
HBS-104 is being studied for sleep deprivation. The only clinical trial of HBS-104 to date enrolls acutely sleep-deprived healthy participants, so the drug has no approved use. Any potential use in sleep deprivation remains investigational and is still being evaluated in early-stage clinical research.
HBS-104 is being developed by Harmony Biosciences Holdings, Inc., which trades on the Nasdaq under the ticker HRMY. Harmony Biosciences is the sponsor of the HBS-104 clinical program, including the Phase 1 study in acutely sleep-deprived healthy participants conducted in the United States.
HBS-104 is in Phase 1 clinical development. It is an investigational small molecule and is not FDA approved. The Phase 1 program consists of one trial, which is currently recruiting, and no trials of HBS-104 have been completed to date.
HBS-104 is being studied in one clinical trial, NCT07848659, titled Study of Single Doses of HBS-104 in Acutely Sleep-deprived Healthy Participants. The Phase 1 trial is recruiting and plans to enroll 12 healthy adult volunteers in the United States. It is randomized, double-blind, and actively controlled.